-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10

Benzinga·12/22/2025 10:40:46
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $8 to $10.